Systems Analysis and Improvement Approach for Prevention of MTC HIV Transmission (SAIA-SCALE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03425136 |
Recruitment Status :
Completed
First Posted : February 7, 2018
Last Update Posted : May 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Other: Systems Analysis and Improvement Approach (SAIA) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | A three-wave stepped-wedge (phased-in) cluster randomized trial, with districts as the unit of randomization (and outcomes assessed at the clinic/individual level within each district) |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Scaling up the Systems Analysis and Improvement Approach for Prevention of Mother-to-Child HIV Transmission in Mozambique |
Actual Study Start Date : | February 1, 2018 |
Actual Primary Completion Date : | September 30, 2021 |
Actual Study Completion Date : | March 31, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: SAIA (Systems Analysis & Improvement)
Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
|
Other: Systems Analysis and Improvement Approach (SAIA)
Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level. |
No Intervention: Control
Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
|
- Maternal retention in care, evaluated using clinic registry data [ Time Frame: 6-months post ART initiation ]Women retained in care (picked up their 6-month pharmacy refill within 15 days of scheduled pickup)
- Maternal viral load assessment, evaluated using clinic registry data [ Time Frame: Within 1 month of delivery (birth) ]Proportion of women on ART with viral load assessment
- Early Infant Diagnosis for HIV, evaluated using clinic registry data [ Time Frame: within 8 weeks of birth ]Proportion of HIV-exposed infants tested for HIV (PCR) within 8 weeks of birth
- Facility Delivery, evaluated using clinic registry data [ Time Frame: At birth ]Proportion of HIV-infected women enrolled in antenatal care with a facility delivery
- Maternal ART Adherence, evaluated using clinic registry data [ Time Frame: At 3 and 6 months post ART initiation ]Proportion of expected ART medicines picked up at study clinics
- Viral Suppression, evaluated using clinic registry data [ Time Frame: Within 1 months of delivery ]Proportion of viral load samples with undetectable viral load (<20 copies/mL)
- Mother-to-Child HIV Transmission Rate, evaluated using clinic registry data [ Time Frame: 6 months postpartum ]Proportion of HIV-exposed infants testing positive for HIV

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria • Woman/infant pair attending pMTCT and linked pediatric HIV screening and treatment services at a public sector health facility
Exclusion Criteria
• None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03425136
Mozambique | |
Manica Province | |
Chimoio, Manica, Mozambique |
Principal Investigator: | Kenneth Sherr, PhD | University of Washington |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Kenneth Sherr, Study Principal Investigator, University of Washington |
ClinicalTrials.gov Identifier: | NCT03425136 |
Other Study ID Numbers: |
STUDY00000645 1R01MH113435 ( U.S. NIH Grant/Contract ) |
First Posted: | February 7, 2018 Key Record Dates |
Last Update Posted: | May 17, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Patient- and aggregate facility-level data will be made available to users who request access to the data after a manuscript based on the primary study results is accepted for publication. User registration will be required in order to access or download files. As part of the registration process, users must agree to the conditions of use governing access to the public release data, including destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgement of the data resource. Registered users will receive user support, as well as information related to errors in the data, future releases, workshops, and publication lists. The information provided to users will not be used for commercial purposes, and will not be redistributed to third parties. Data from focus group discussions and key informant interviews will not be available because of human subjects protections constraints. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Analytic Code |
Time Frame: | After a manuscript with primary study results is accepted for publication. |
Access Criteria: | User registration will be required in order to access or download files. As part of the registration process, users must agree to the conditions of use governing access to the public release data, including destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgement of the data resource. The information provided to users will not be used for commercial purposes, and will not be redistributed to third parties. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Prevention of Mother-to-Child HIV Transmission HIV PMTCT |